Georgetown University

Samsung Electronics Co., Ltd.

Shangzi Wang

Jill P Smith

Louis M Weiner

Sandra Jablonski

Sandeep Nadella

Ji Min Lee

Kyung Ah Kim

Bo Gyou Kim

Louis Weiner

Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.

Treating cancer with a CCK receptor inhibitor and an immune checkpoint inhibitor

A target substance used for combination treatment with an anti-c-Met antibody, a pharmaceutical composition for combination administration for preventing and/or treating cancer including an anti-c-Met antibody and an inhibitor against the target substance as active ingredients, a method for preventing and/or treating cancer including co-administering an anti-c-Met antibody and an inhibitor against the target substance, and a method for screening a drug for preventing and/or treating cancer using the target substance.

Combination therapy for the treatment of cancer using an anti-C-met antibody

Growing community of inventors

Derwood, MD, United States of America

Shangzi Wang